Targeting extrachromosomal DNA to treat glioblastoma
Extrachromosomal DNA as a Targetable Mechanism in Glioblastoma
['FUNDING_R01'] · YALE UNIVERSITY · NIH-10744242
This study is looking at a special type of DNA found in brain cancer cells that helps tumors grow and resist treatment, and the researchers want to find new ways to target this DNA to improve care for people with glioblastoma.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | YALE UNIVERSITY (nih funded) |
| Locations | 1 site (NEW HAVEN, UNITED STATES) |
| Trial ID | NIH-10744242 on ClinicalTrials.gov |
What this research studies
This research investigates the role of extrachromosomal DNA (ecDNA) in glioblastoma, a type of brain cancer, focusing on how it contributes to tumor growth and resistance to treatment. The project aims to understand the origins and replication mechanisms of ecDNA, which is prevalent in tumor cells and can amplify oncogene expression. By developing new technologies to detect and characterize ecDNA, the researchers hope to identify potential therapeutic strategies that could inhibit its function and improve treatment outcomes for patients with glioblastoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who may benefit from innovative therapeutic strategies targeting ecDNA.
Not a fit: Patients with other types of cancer or those without glioblastoma may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that specifically target the mechanisms driving glioblastoma progression.
How similar studies have performed: While the role of ecDNA in cancer is recognized, this specific approach to targeting ecDNA in glioblastoma is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
NEW HAVEN, UNITED STATES
- YALE UNIVERSITY — NEW HAVEN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: VERHAAK, ROEL GW — YALE UNIVERSITY
- Study coordinator: VERHAAK, ROEL GW
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer